Financial Performance - The company achieved a main business revenue of 2,645.07 million RMB in 2023, representing a growth of 25.11% compared to the previous year[6]. - The company's operating revenue for 2023 reached approximately CNY 2.65 billion, representing a 24.59% increase compared to CNY 2.13 billion in 2022[57]. - Net profit attributable to shareholders for 2023 was approximately CNY 416.12 million, a significant increase of 130.58% from CNY 180.47 million in 2022[57]. - The net profit attributable to shareholders of the listed company increased by 130.58% to 416.12 million yuan, while the net profit excluding non-recurring gains and losses rose by 141.52% to 383.41 million yuan[109]. - The net cash flow from operating activities increased by 174.30% to approximately CNY 634.45 million, driven by substantial growth in revenue and operating profit[59]. - The company's total assets at the end of 2023 were approximately CNY 7.11 billion, reflecting a 3.09% increase from CNY 6.89 billion at the end of 2022[57]. - The net assets attributable to shareholders increased by 2.46% to approximately CNY 5.65 billion at the end of 2023[57]. - The company's basic earnings per share increased by 134.62% to CNY 2.44 in 2023, compared to CNY 1.04 in 2022[85]. Research and Development - The company has invested a total of 7,033.32 million RMB in various R&D projects, with a cumulative investment of 25,963.14 million RMB[11]. - The R&D team consists of 366 personnel, accounting for 16.96% of the total workforce, with an average salary of 33.04 thousand yuan[18]. - The company has established multiple R&D platforms, including a national-level enterprise technology center and a national postdoctoral research station, enhancing its research capabilities[21]. - Research and development expenses amounted to CNY 220,098,300, representing a 20.81% increase from the previous year, accounting for 8.29% of total revenue[82]. - The company is actively increasing R&D investment to develop new technologies and products, focusing on core technology transformation[184]. Product Development and Innovation - The company is conducting clinical trials for several new products, including a new type of artificial lens and a high-permeability scleral lens, with expected product approvals in early 2024[11]. - The company is developing innovative products such as a new type of cross-linked chitosan gel and a long-acting cross-linked sodium hyaluronate injection, which are expected to enhance treatment efficacy[11]. - The company successfully launched a new hydrophobic aspheric intraocular lens product in June 2023, with several other innovative products in various stages of clinical trials[82]. - The company has developed a second-generation PRL product for myopia correction, with clinical trials progressing smoothly, and high-permeability scleral lenses expected to complete registration testing by February 2024[157]. - The company has developed a large-scale sodium hyaluronate injection product that is now in the clinical application stage[191]. Market Expansion and Strategy - The company has expanded its international presence through acquisitions, focusing on transferring advanced technologies and products to the domestic market[1]. - The company plans to continue its market expansion and product development strategies, focusing on high-margin products like hyaluronic acid[3]. - The company aims to enhance the brand image of its high-end hyaluronic acid product "Haimi" and expand market penetration in 2024[127]. - The company is focusing on expanding its product matrix across four major categories: hyaluronic acid, epidermal repair gene engineering preparations, RF, and laser equipment, catering to diverse consumer needs in medical and home beauty applications[160]. - The company plans to focus on the ophthalmology sector in 2024, adapting to changes in industry policies and leveraging its multi-brand product line advantages[126]. Operational Efficiency and Cost Management - The company has reduced cash outflow from investment activities due to effective cash management, particularly in the purchase of bank certificates[5]. - The company emphasized the importance of cash flow management, noting efforts to reduce accounts receivable and enhance collection efforts[59]. - The company has established a procurement center to enhance operational efficiency and reduce costs through centralized purchasing of raw materials and equipment[178]. - The company is actively monitoring overdue accounts receivable and has reduced or stopped credit sales to clients with credit risks, leading to a decrease in accounts receivable balance[4]. Market Position and Brand Influence - The company's ophthalmic viscoelastic product has maintained a market share of 16 consecutive years as the leading product in the domestic market[16]. - The company has a leading brand influence in various treatment areas, with its products ranking among the top in sales within their respective categories[27]. - The company is the only domestic manufacturer with a full range of orthopedic sodium hyaluronate injection products in 2ml, 2.5ml, and 3ml specifications[17]. - The company holds a 46.45% market share in the orthopedic joint cavity viscoelastic supplement market in China, maintaining the leading position for nine consecutive years[172]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.90% in 2022, also maintaining this position for 16 years[183]. Challenges and Future Outlook - The company has not yet achieved profitability since its listing, as indicated in the report[44]. - The management highlighted future growth strategies, although specific commitments were not made to investors[60]. - The group plans to advance the registration of several key products in 2024, including hydrophobic aspheric multifocal intraocular lenses and innovative intraocular filling biological gel products[142]. - The group aims to enhance its operational efficiency and core competitiveness through the integration of acquired companies and resource allocation in 2024[153]. - The Chinese medical aesthetics market is projected to grow at a compound annual growth rate of 15%-20% over the next five years, driven by increasing consumer demand and a low penetration rate compared to other countries[132].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 645,995,271.22, representing a year-on-year increase of 5.68%[6] - The net profit attributable to shareholders for Q1 2024 was CNY 97,541,532.98, reflecting a growth of 20.16% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,217,851.02, which is an increase of 33.05% year-on-year[6] - The basic earnings per share for Q1 2024 was CNY 0.58, up by 23.40% from CNY 0.47 in Q1 2023[18] - Net profit for the current period reached 92,488,777.12, an increase from 84,951,683.69 in the previous period, representing a growth of approximately 6.4%[41] - Total revenue from operating profit was 114,427,839.61, slightly up from 111,265,909.95, indicating a growth of about 1.9%[41] - The company's earnings per share attributable to shareholders increased to 97,541,532.98 from 81,177,581.15, representing a growth of about 20.2%[41] Assets and Liabilities - The total assets at the end of Q1 2024 amounted to CNY 7,192,952,822.94, a 1.23% increase from the end of the previous year[26] - As of March 31, 2024, total current assets amounted to approximately RMB 3.75 billion, slightly down from RMB 3.75 billion at the end of 2023[32] - The company’s total assets reached approximately RMB 7.19 billion, up from RMB 7.11 billion at the end of 2023[32] - The company's total liabilities amounted to 1,070,720,682.01, a decrease from 1,088,203,977.97, reflecting a reduction of approximately 1.6%[45] - The total equity attributable to shareholders increased to 5,755,069,480.72 from 5,650,064,203.23, marking an increase of about 1.9%[45] Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY 75,969,702.64, a decrease of 4.96% compared to the previous year[6] - The company reported a net cash inflow from investment activities of CNY 159,290,447.77 for Q1 2024, compared to CNY 156,184,009.96 in the same period last year[19] - The company reported a net cash inflow from financing activities of approximately RMB 42.14 million, a significant improvement from a net outflow of RMB 20.94 million in the previous period[38] Research and Development - The total R&D expenditure for Q1 2024 was CNY 64,900,123.30, which accounted for 10.05% of the operating revenue, an increase of 1.28 percentage points year-on-year[26] Shareholder Information - The top ten shareholders hold a combined 88.68% of the shares, with the largest shareholder owning 28.17%[28] Government Subsidies - The company received government subsidies amounting to CNY 3,820,341.64 during the reporting period[26] - Government subsidies received during the reporting period decreased significantly compared to the same period last year, leading to a 75.83% decline in non-recurring net gains[28] Inventory and Cash Management - Cash and cash equivalents at the end of the reporting period were RMB 846.19 million, an increase from RMB 772.22 million at the end of the previous year[38] - Inventory as of March 31, 2024, was approximately RMB 533.64 million, showing a slight increase from RMB 526.17 million at the end of 2023[32] Strategic Focus - The company continues to focus on high-margin hyaluronic acid products, contributing to overall gross profit growth[28] - The company is actively exploring new product development and market expansion strategies to enhance its competitive position[28] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 1.72%, an increase of 0.24 percentage points year-on-year[26] - Interest income decreased to 17,894,671.58 from 19,194,643.89, a decline of approximately 6.8%[41] - Other comprehensive income after tax showed a significant drop to -21,216,593.79 from 3,063,929.44, indicating a negative shift[41] - The company reported a decrease in credit impairment losses to -476,413.55 from -2,445,931.34, showing an improvement in credit quality[41] - The company’s capital reserve decreased to 2,903,610,489.65 from 2,980,937,753.79, a decline of approximately 2.6%[45]

| 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐敏捷先生；本公司之非執行董事為游捷女士及黃明 | | 第 2 頁 共 2 頁 v 1.1.2 EF005 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 紅股或紅利認股權證公告 | | | 發行人名稱 | 上海昊海生物科技股份有限公司 | | 股份代號 | 06826 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2023年12月31日止年度之儲備轉增股本（更新） | | 公告日期 | 2024年4月26日 | | 公告狀態 | 更新公告 | | ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海昊海生物科技股份有限公司 | | 股份代號 | 06826 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2023年12月31日止年度的末期股息（更新） | | 公告日期 | 2024年4月26日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | (1)股東批准日期；(2)香港過戶登記處相關信息；(3)股息派發日；及(4) 股息所涉及的代 | | 扣所得稅信息。 | | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2023年12月31日 | | 宣派股息的報告期末 | 2023年12月31日 | | 宣派股息 | 每 股 1 RMB | | 股東批准日期 | 2 ...

| 会议须知 1 | | --- | | 会议议程 3 | | 关于公司董事会 2023 年度工作报告的议案 5 | | 关于公司监事会 2023 年度工作报告的议案 13 | | 关于公司截至 2023 年 12 月 31 日止年度财务报表的议案 17 | | 关于公司董事、监事 2024 年薪酬计划的议案 18 | | 关于聘请公司 2024 年度财务报告审计机构及内部控制审计机构的议案 20 | | 关于修订《公司章程》、《股东大会议事规则》、《董事会议事规则》及《监事会议 | | 事规则》的议案 21 | | 关于公司 2023 年度利润分配及资本公积金转增股本预案的议案 23 | | 关于授予董事会回购 H 股的一般性授权的议案 25 | | 独立非执行董事 2023 年度述职报告 27 | 上海昊海生物科技股份有限公司 上海昊海生物科技股份有限公司 2023 年度股东周年大会、 2024 年第一次 A 股类别股东大会 及 2024 年第一次 H 股类别股东大会 会议资料 二〇二四年五月二十九日·上海 1 证券代码：688366 证券简称：昊海生科 2024 年第一次 H 股类别股东大会 会议须知 ...

证券代码：688366 证券简称：昊海生科 公告编号：2024-022 上海昊海生物科技股份有限公司 关于召开 2023 年度股东周年大会、2024 年第一次 A 股类别股东大会及 2024 年第一次 H 股类别股东大会 的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2023 年度股东周年大会、2024 年第一次 A 股类别股东大会、2024 年第一次 H 股类别股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2024 年 5 月 29 日 14 点 00 分 召开地点：上海市长宁区虹桥路 1386 号文广大厦 24 楼 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 网络投票起止时间：自 2024 年 5 月 29 日 至 2024 年 5 月 29 日 采用上海证券交 ...

（股份代號：6826） 董事會會議召開日期 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二 零二四年四月二十九日（星期一）舉行董事會會議，藉以（其中包括）審議及通過本 公司及其附屬公司截至二零二四年三月三十一日止三個月之第一季度業績及其發 佈。 承董事會命 上海昊海生物科技股份有限公司 主席 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 中國上海，二零二四年四月十七日 侯永泰 ...

2023 年 報 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 主席致辭 | 5 | | 管理層討論與分析 | 7 | | 董事會報告 | 26 | | 企業管治報告 | 54 | | 環境、社會及管治報告 | 74 | | 董事、監事及高級管理人員簡介 | 125 | | 獨立核數師報告 | 133 | | 綜合損益及其他綜合收益表 | 139 | | 綜合財務狀況表 | 141 | | 綜合權益變動表 | 143 | | 綜合現金流量表 | 145 | | 財務報表附註 | 148 | | 釋義 | 246 | | 技術詞彙 | 250 | 目 錄 上海昊海生物科技股份有限公司 2 公司資料 第五屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 沈紅波先生 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第五屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 宋霄女士 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港公司治理公 ...

Financial Performance - Total revenue for 2023 reached RMB 2,634,910,000, an increase of 25.2% compared to RMB 2,103,438,000 in 2022[6] - Net profit attributable to shareholders was RMB 416,121,000, up 130.5% from RMB 180,470,000 in the previous year[6] - Earnings per share increased to RMB 2.44 in 2023, compared to RMB 1.04 in 2022[6] - The company achieved a total revenue of RMB 2,634.91 million in 2023, representing a year-on-year increase of 25.27%[7] - The company’s net profit attributable to ordinary shareholders was approximately RMB 416.12 million, an increase of about RMB 235.65 million or 130.58% from RMB 180.47 million in 2022[42] - The overall gross margin for the company was 70.34% in 2023, up from 68.79% in 2022, primarily due to strong sales performance of high-margin hyaluronic acid products[37] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 7,105,497,000, a rise from RMB 6,892,399,000 in 2022[6] - Total liabilities increased to RMB 1,088,204,000 from RMB 990,016,000 in 2022, resulting in a debt-to-asset ratio of 15.3%[6] - Total current liabilities of the group as of December 31, 2023, were approximately RMB 715.95 million, an increase of about RMB 204.67 million or 40.03% compared to December 31, 2022[43] - The total liabilities of the group as of December 31, 2023, were approximately RMB 1,088.20 million, with a debt-to-asset ratio of 15.31%, an increase of 0.95 percentage points from 14.36% as of December 31, 2022[48] Research and Development - Research and development efforts are focused on innovative technologies to enhance product offerings and competitiveness[6] - Research and development expenses amounted to RMB 220.10 million, an increase of 20.81% year-on-year, accounting for 8.35% of total revenue[11] - The company is actively developing innovative high-end artificial lens products, with several clinical trials underway for new technologies[18] - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with several innovative products entering the registration phase[11] Market Expansion and Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[6] - Management remains optimistic about future performance, expecting continued revenue growth and improved profitability[6] - The company is exploring potential mergers and acquisitions to accelerate growth and market expansion[6] - The company aims to expand its market share in the medical aesthetics sector by promoting its differentiated hyaluronic acid products through a broad sales network in 2024[36] Product Performance - The ophthalmic product line generated revenue of RMB 924.65 million, accounting for 35.10% of total revenue, with a growth rate of 20.72%[10] - The medical beauty and wound care product line saw revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a year-on-year growth of 41.44%[10] - The company's hyaluronic acid product line includes three generations, with the first generation achieving sales of RMB 599.41 million, accounting for 56.94% of total revenue in 2023, reflecting a growth of 95.78% year-on-year[23] - The company's ophthalmic products achieved revenue of RMB 924.65 million, an increase of approximately RMB 158.68 million, representing a growth rate of 20.72% compared to the previous year[14] Shareholder Returns - The board proposed a final dividend of RMB 1.00 per share for the year 2023, reflecting a 150% increase compared to the previous year[7] - The company plans to distribute a final dividend of RMB 1.00 per share for the year ending December 31, 2023, totaling RMB 167,360,375.00[58] - The company’s profit distribution policy emphasizes a stable and sustainable return to investors, with cash dividends prioritized when conditions allow[64] Corporate Governance - The company has established a corporate governance structure to protect shareholder rights and enhance accountability[123] - The company has adhered to all applicable provisions of the corporate governance code during the reporting period[117] - The board consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors[123] - The company has established internal policies to ensure the board receives independent views and opinions, with independent non-executive directors entitled to seek independent professional advice at the company's expense[127] Risk Management - The company has established a stable and effective risk management mechanism, including an internal audit system and risk assessment management system[183] - The company faces potential risks from intensified market competition, which could impact its market share and profitability[157] - Regulatory changes in China's healthcare system may increase compliance costs and reduce product demand if the company fails to adapt[158] Employee and Management - The total employee compensation for the group during the reporting period was approximately RMB 630.08 million, with a total workforce of 2,158 employees[44] - The company has implemented a restricted stock incentive plan approved on March 7, 2022, to attract and retain core management and technical personnel, with a total of 1,800,000 shares granted under this plan[91] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[84] Community and Social Responsibility - The company made donations amounting to RMB 100,000 during the reporting period[119] - Community engagement includes donations, public welfare activities, and industry meetings[200] Compliance and Legal Matters - The company has not encountered any corruption or bribery lawsuits during the reporting period, reflecting its commitment to integrity and compliance[186] - The company has complied with all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules regarding related party transactions[116]

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price not specified [9] Core Insights - The company reported a revenue of 2.654 billion yuan in 2023, representing a year-on-year growth of 24.59% - The net profit attributable to the parent company reached 416.12 million yuan, a significant increase of 130.58% year-on-year - The gross margin for 2023 was 70.46%, an increase of 1.51 percentage points compared to the previous year, driven by the rising revenue share of high-margin hyaluronic acid products [6][7][15] Financial Performance Summary - Revenue growth was primarily fueled by the sales of hyaluronic acid products, which generated 602 million yuan, up 95.54% year-on-year - The revenue from artificial lens products was 382 million yuan, reflecting a 37% increase, attributed to the recovery in cataract surgeries and centralized procurement policies - The revenue from sodium hyaluronate injection products was 314 million yuan, a growth of 20.83%, supported by the company's leading position in orthopedic joint cavity viscoelastic supplements [6][7] Cost and Expense Analysis - The sales expense ratio was 30.69%, down 1.21 percentage points year-on-year - The management expense ratio was 15.74%, down 3.14 percentage points year-on-year - The R&D expense ratio was 8.29%, down 0.26 percentage points year-on-year [7] Future Outlook - The company plans to focus on the registration and clinical trials of several key projects in 2024, including advanced artificial lenses and new-generation products [6][7] - Revenue forecasts for 2024-2026 are projected at 2.572 billion yuan, 3.123 billion yuan, and 3.695 billion yuan respectively, with net profits expected to be 436.33 million yuan, 556.89 million yuan, and 665.12 million yuan [15][19]